Invitrogen Corporation (IVGN) Strengthens DNA/RNA Purification Product Line With Acquisition Of DNA Research Innovations Ltd.
10/19/2005 5:11:58 PM
Invitrogen Corporation (Nasdaq:IVGN) today announced it has acquired DNA Research Innovations, Ltd. (DRI), a privately-held company based in Kent, England, that develops and markets innovative products for the purification of DNA and other nucleic acids. DRI's patent-protected ChargeSwitch(R) Technology (CST(R)) is versatile, works in multiple formats, produces high purity and yield, and is safe and easy-to-use. According to the terms of the deal, Invitrogen paid $35 million in cash, and may make contingent payments of up to $30 million based upon the completion of certain R & D milestones. The deal is not expected to change Invitrogen's guidance for the fourth quarter of 2004.
comments powered by